Improved Novel VaccIne CombinaTion InflUenza Study (INVICTUS)

• ClinicalTrials.gov Identifier: NCT03300362
• Recruitment Status: Terminated
• First Posted: October 3, 2017
• Last Update Posted: November 23, 2018
• Sponsor: Vaccitech (UK) Limited
• Collaborator: University of Oxford
• Information provided by (Responsible Party): Vaccitech (UK) Limited

Study Description

Brief Summary:

A Phase IIb randomised, participant-blinded, placebo-controlled, multi-centre phase IIb efficacy study in 2030 volunteers aged 65 and over. The study will assess the safety and efficacy of the co-administration of a viral vectored vaccine, MVA- NP+M1, and the annual recommended licensed inactivated influenza vaccine (IIV). Within the main cohort 100 participants will be recruited to an immunology sub-cohort.

Condition or disease	Intervention/treatment	Phase
Influenza	Drug: Seasonal influenza vaccine; Drug: MVA-NP+M1; Drug: Sodium chloride	Phase 2

Detailed Description:

The efficacy of current seasonal influenza vaccines is limited in the face of antigenic mismatch between circulating viral strains and those in the given vaccine. Additionally vaccination in older adults, a major target group for vaccination, prevents laboratory-confirmed influenza in only 30-40% compared to 70-90% in young adults. The hypothesis in this Phase IIb efficacy study is that a new vaccine MVA-NP+M1 with licensed inactivated influenza vaccine (IIV) in the older age group will be able to induce immune responses that protect individuals against influenza illness, severity of symptoms and reduce viral shedding, thereby increasing the protection conferred by seasonal influenza vaccine alone. A total of 2030 participants who are 65 years of age or over and eligible for annual seasonal influenza vaccination and provide informed consent will be recruited to the study. Potential volunteers will be mailed an invitation to take part by their GPs or recruited by local advertisements. Participants will be randomised to receive either MVA- NP+M1 with licensed IIV or saline placebo with licensed IIV. In the first 28 days after vaccination, participants will record adverse events using an electronic or paper diary. The participants will be contacted by telephone 1 day and 7 days post-vaccination to enquire about any serious adverse events and support follow up. During influenza season participants will record weekly whether or not they have had an influenza like illness (ILI). For every ILI episode experienced, the participants will record the severity of their symptoms daily. Among the participants, a total of 100 volunteers (50 in each group) will be recruited into an immunology sub-cohort. They will have blood samples collected on the day of vaccination, 1 week, 3 weeks and 26 weeks post-vaccination for monitoring of laboratory adverse events and immunogenicity purposes.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 862 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Participant)
• Masking Description: Investigators recording clinical outcomes will also be blinded
• Primary Purpose: Prevention
• Official Title: A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above
• Actual Study Start Date: October 13, 2017
• Actual Primary Completion Date: October 31, 2018
• Actual Study Completion Date: October 31, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: Seasonal influenza & MVA-NP+M1; Two vaccinations will be administered: Seasonal influenza vaccine & MVA-NP+M1	Drug: Seasonal influenza vaccine; Seasonal influenza vaccine; Other Name: Quadrivalent Influenza Vaccine; Drug: MVA-NP+M1; Trial vaccine
Placebo Comparator: Seasonal influenza & saline placebo; Two vaccinations will be administered: Seasonal influenza vaccine & sodium chloride	Drug: Seasonal influenza vaccine; Seasonal influenza vaccine; Other Name: Quadrivalent Influenza Vaccine; Drug: Sodium chloride; Saline placebo

Outcome Measures

Primary Outcome Measures :

1. Number of days with moderate or severe influenza-like symptoms [ Time Frame: 6-7 months ]
   Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries

Secondary Outcome Measures :

1. Incidence of influenza-like-illness [ Time Frame: 6-7 months ]
   Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries
2. Severity of influenza-like symptoms [ Time Frame: 6-7 months ]
   Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries
3. Duration of influenza-like-illnes [ Time Frame: 6-7 months ]
   Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries
4. Occurrence of GP consultations from respiratory illness [ Time Frame: 6-7 months ]
   Throughout the influenza season - self-reported and Medical Records
5. Occurrence of hospitalisations and deaths due to respiratory illness [ Time Frame: 6-7 months ]
   Throughout the influenza season - self-reported and Medical Records
6. Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination [ Time Frame: Day 0-7 ]
   Self-reported symptoms recorded using electronic or paper diaries
7. Occurrence of serious adverse events during the whole study duration [ Time Frame: 6-7 months ]
   Telephone calls on Day 1-3, day 7-9 and every 3-4 weeks throughout volunteers' participation in the trial
8. Occurrence of unsolicited adverse events for 28 days following vaccination [ Time Frame: Day 0-28 ]
   Self-reported symptoms recorded using electronic or paper diaries
9. Frequency of influenza-specific T-cells measured by IFNg ELISpot [ Time Frame: 6-7 months ]
   To assess the immunogenicity of MVA-NP+M1 in combination with the recommended licensed inactivated influenza vaccine in adults aged 65 years and above
10. Geometric mean titre of influenza-specific neutralising antibodies [ Time Frame: 6-7 months ]
    To assess the immunogenicity of MVA-NP+M1 in combination with the recommended licensed inactivated influenza vaccine in adults aged 65 years and above
11. Breadth of influenza-specific T-cells and antibodies [ Time Frame: 6-7 months ]
    To assess the immunogenicity of MVA-NP+M1 in combination with the recommended licensed inactivated influenza vaccine in adults aged 65 years and above

Other Outcome Measures:

1. Estimated frequency of influenza infection using historical data on the proportion of ILIs that is caused by influenza virus infection. [ Time Frame: 6-7 months ]
   To explore novel clinical endpoints for future Phase III efficacy trials of influenza vaccines

Eligibility Criteria

• Ages Eligible for Study: 65 Years and older (Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Volunteer is willing and has capacity to provide written informed consent for participation in the trial (in the Investigator's opinion).
• Male or female adults, aged 65 years and above
• Able and willing (in the Investigator's opinion) to comply with all study requirements
• Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
• Eligible to receive seasonal influenza vaccine

Exclusion Criteria:

• Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine (e.g. egg allergy)
• Ongoing terminal illness with a life expectancy estimated to be approximately <6 months.
• Continuous use of oral anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban)
• Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study
• Participation in another clinical trial of an investigational medicinal product in the 30 days preceding enrolment, or planned use during the study period
• Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data
• Receipt of annual seasonal influenza vaccine prior to enrolment (for the same influenza season volunteers are recruited in)
• Not willing to comply with study procedures

Contacts and Locations

Locations

United Kingdom

The Boathouse Surgery

Pangbourne, Berkshire, United Kingdom, RG8 7DF

Wokingham Medical Centre

Wokingham, Berkshire, United Kingdom, RG40 1XS

Bicester Health Centre

Bicester, Oxfordshire, United Kingdom, OX26 6AT

Centre for Clinical Vaccinology and Tropical Medicine (CCVTM

Oxford, Oxfordshire, United Kingdom, OX3 7LJ

Windrush Health Centre

Witney, Oxfordshire, United Kingdom, OX28 6JS

Sponsors and Collaborators

Vaccitech (UK) Limited

University of Oxford

Investigators

• Principal Investigator: Christopher Butler; University of Sussex

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Swayze H, Allen J, Folegatti P, Yu LM, Gilbert S, Hill A, Ellis C, Butler CC. A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol. F1000Res. 2019 May 23;8:719. doi: 10.12688/f1000research.19090.1. eCollection 2019.

• Responsible Party: Vaccitech (UK) Limited
• ClinicalTrials.gov Identifier: NCT03300362
• Other Study ID Numbers: FLU007 INVICTUS
• First Posted: October 3, 2017
• Last Update Posted: November 23, 2018
• Last Verified: May 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Influenza, Human; Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Vaccines; Immunologic Factors; Physiological Effects of Drugs